政府新闻
复星新冠肺炎药丸抵达上海社区医院 2023-01-05
Fosun's Covid-19 Pill Arrives at Shanghai Community Hospitals
Fosun Pharma's Azvudine, China's first self-developed oral medication for Covid-19, has started to enter Shanghai's lower-level hospitals as the Chinese pharmaceutical giant steps up distribution amid a new wave of Covid-19 following the relaxation of pandemic prevention measures, Shanghai Securities News reported on Wednesday.
Jointly developed with Henan Genuine Bio, Azvudine is now available at 113 community hospitals and 115 secondary and tertiary hospitals in Shanghai.
Azvudine was greenlit for the treatment of the novel coronavirus by medical regulators in July last year with certain conditions attached. There are only three orally taken Covid-19 tablets available in China and the other two are developed by overseas pharma giants, namely Pfizer's Paxlovid and Merck's Monoravir.
Azvudine was included in China's bulk-buying program last month, which gives medicines access to the country's vast medical insurance network, at a price of CNY270 (USD39) per bottle of 35 tablets.
Since then, Shanghai-based Fosun Pharma has been accelerating distribution across the country and has teamed up with pharma giants Sinopharm and China Resources Pharmaceutical to extend its network.
Source: Yicai
